Skip to content

James Larkin

University of Siena

4 papers in the Anchorcite directory, published between 2015 and 2017, cited 25,734 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine · 2015 · 8,341 citations

    BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab…

  2. Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations

    BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase…

  3. Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2015 · 5,913 citations

    BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell…

  4. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2017 · 5,446 citations

    BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS:…

Metadata from OpenAlex (CC0).